C. diff Survey Results: Published Research

Between the spring and autumn of 2016, the GI Society hosted a survey on our English and French websites to help understand how CDI affects people. Thank you to everyone who shared your experiences with us by participating in this survey. Your opinions are very important to us and they help shape our advocacy. We [...]

By |2020-01-10T14:27:36-08:00January 10, 2020|News|

Short-sighted policies, clickbait savings, and long-term damage to IBD patients

December 18, 2019 Gail Attara President & Chief Executive Officer, Gastrointestinal Society President, Canadian Society of Intestinal Research Alberta’s policy decision to switch the treatments of thousands of patients to biosimilars comes under the guise of presumed cost-savings and at the behest of a few sacrifices from patients. The non-medical switch policy, announced on December [...]

By |2019-12-18T13:40:14-08:00December 18, 2019|News|

IBD Patients: What’s Missing in Your Care?

We invite you to take part in this survey about communication between patients and their physicians regarding inflammatory bowel disease (primarily Crohn’s disease and ulcerative colitis). This is a follow-up to a survey we conducted in 2018 about the unmet need in inflammatory bowel disease and we are opening it up to global input. The [...]

By |2019-09-26T14:32:12-07:00September 26, 2019|News|

Biosimilars Survey for Patients

The Gastrointestinal Society represents Canadian patients on a variety of healthcare fronts, including access to medications. We have designed this survey to help us understand your opinions and outlook regarding biosimilar medications. We will use this information anonymously and in aggregate to shape future programming and to inform community members, healthcare professionals, and health policy [...]

By |2019-09-26T14:26:25-07:00September 25, 2019|News|

Balancing Act: Cost Containment vs. Patient Health Outcomes

Have you had your medicine switched? We want to help! Contact us to share your story. If you have any opinions on biosimilars or biologics, please take our survey on biosimilars. If you have Crohn's disease or ulcerative colitis, please take our survey on IBD. September 5, 2019 Gail Attara, President & Chief [...]

By |2019-11-08T14:54:36-08:00September 5, 2019|News|

Video: BadGut® Lecture on Medical Canabis

If you have been unable to attend any of our BadGut® Lectures on Medical Cannabis in person, you can view a recording of a lecture we held in Vancouver, BC, on June 10, 2019, by watching the video below. This lecture provides a basic overview of medical cannabis and the endocannabinoid system and cover topics [...]

By |2019-07-30T14:25:05-07:00July 31, 2019|News|

Don’t Tax Medicine Campaign

Unlike other medicines, medicinal cannabis is subject to sales tax. Since cannabis is already quite expensive, many patients struggle to afford the high price of keeping their symptoms controlled. Canadians for Fair Access to Medical Marijuana (CFAMM) is intensifying their Don’t Tax Medicine campaign to oppose ALL taxes on medical cannabis. The GI Society is [...]

By |2019-02-13T13:34:23-08:00February 13, 2019|News|

Survey Results: The Unmet Need of IBD in Canada

The GI Society represents Canadians living with gastrointestinal diseases and disorders, including those who have inflammatory bowel disease (IBD). IBD is an umbrella term that primarily refers to Crohn’s disease and ulcerative colitis. These diseases are characterized by inflammation in the digestive tract. In ulcerative colitis, this inflammation is limited to the inner mucosa of [...]

By |2019-01-18T14:37:45-08:00January 18, 2019|News|
Load More Posts